Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has maintained a Neutral rating on Vera Therapeutics (NASDAQ:VERA) and increased the price target from $16 to $21.

January 26, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Vera Therapeutics but raises the price target from $16 to $21.
The increase in price target by a reputable analyst like Laura Chico could lead to positive investor sentiment in the short term, potentially driving the stock price up. However, since the rating remains Neutral, the impact may not be as strong as it would be with an upgrade to a Buy rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100